EDGE
Get a demo
Log In

Protai

AI Drug Discovery
Segments:
AI Drug Discovery & Development
?
Product stage:
Seed
?

Protai is a drug discovery company in Israel that leverages AI and proteomics to develop novel therapeutics for complex diseases. The company’s drug discovery approach involves the mapping of diseases based on their protein-level data and interactions, to observe cellular functions. It uses its proteome database—reportedly the largest in the world—with over 50,000 clinical samples gathered by harmonizing large sets of data from 6,000 research papers. It is also building machine learning models to identify more than one million proteo-forms including protein-protein interactions, and post-translational modifications of proteins. 

Protai’s platform leverages Google subsidiary DeepMind’s AlphaFold, an AI-powered protein model predicting platform, to improve the prediction of protein-protein interactions and drug-target interactions.

The company has not disclosed its drug pipeline; however, in a proof-of-concept, it reported that its platform has identified several high-value targets for lung cancer, which are currently being researched. 

Founded in 2021, Protai emerged from stealth in January 2022, raising USD 8 million in seed funding. It has earmarked the funds to further develop its AI platform, advance its drug programs, and enhance its partnerships with pharmaceutical companies. 

AI Drug Discovery

AI Drug Discovery

Key stats
Featured companies
158
Total funding (USD)
25.1 Bn
Total addressable market (USD)
39.6 Bn
Key competitors
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

Recent Updates

Funding
Mar 15, 2023
Protai raises additional USD 12 million in seed funding
AI Drug Discovery
Funding
Jan 5, 2022
Protai emerges from stealth with USD 8 million seed funding
AI Drug Discovery

Company Brief


HQ location:
Tel Aviv ISR
Founded year:
2021
Employees:
11-50
Total Funding:
USD 20.0 million
Last Funding
USD 12.0 million, Mar 2023

Funding


Investors


No investor data is available

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.